Key result
DNA vaccination with the major structural protein VP1 protected 72.2% of mice from lethal coxsackievirus B3 challenge, whereas VP1 expressed by recombinant vaccinia viruses was much less efficient.
Why the study?
Does DNA vaccination with VP1 protect mice against lethal coxsackievirus B3 infection?
Does DNA vaccination with VP1 protect mice against lethal coxsackievirus B3 infection?
DNA vaccination with the major structural protein VP1 provides significant protection against lethal coxsackievirus B3 infection in a mouse model.
DNA vaccination with VP1 merits testing in additional CVB3 models; leaves open translation to humans or other platforms.
Vaccination with DNA and recombinant vaccinia viruses (rec.VV) has been studied with the coxsackievirus B3 (CVB3) model system. Plasmids encoding all structural proteins of CVB3, when injected intramuscularly, induced only low levels of virus-specific antibodies. However, DNA vaccination with the major structural protein VP1 protected 72.2% of mice from lethal challenge, whereas VP1 expressed by rec.VV was much less efficient.
No takes yet. Share an insight, caveat, or question.
Henke et al. (1998) studied Coxsackievirus B3 (CVB3) infection. DNA vaccination with the major structural protein VP1 vs. VP1 expressed by recombinant vaccinia viruses (rec.VV) was evaluated on Protection from lethal challenge. DNA vaccination with the major structural protein VP1 protected 72.2% of mice from lethal coxsackievirus B3 challenge, whereas VP1 expressed by recombinant vaccinia viruses was much less efficient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: